Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase II Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Sponsor: Celgene Corporation
A PHASE2 clinical study on CLL and Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 13 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Feb 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Sep 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Oct 2021 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .